Trials / Completed
CompletedNCT00805909
NI-0401 in Patients With Acute Renal Allograft Rejection
A Phase IIa, Open-Label, Dose-Titration, Multicenter Study to Assess the Safety and Preliminary Efficacy of NI-0401 in Patients With Acute Cellular Renal Allograft Rejection
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Light Chain Bioscience - Novimmune SA · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine the safety and tolerability of NI-0401 and whether NI-0401 can reverse BpACR.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NI-0401 | 5 daily infusions with escalating doses of NI-0401 |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2008-12-10
- Last updated
- 2009-06-09
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00805909. Inclusion in this directory is not an endorsement.